Trial Condition(s):

Lymphoma, Follicular, Non-Hodgkin Lymphoma

A prospective observational study to evaluate the quality of life and the costs in a real life setting in patients who are treated with 90Y-Zevalin

Bayer Identifier:

13455

ClinicalTrials.gov Identifier:

NCT01164696

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with model-predicted data at reimbursement on the basis of a clinical trial in heavily pre-treated NHL.

Inclusion Criteria
- Advanced cancer of the lymph nodes of follicular type at study inclusion
 - The patient has relapsed or has refractory disease, after previous treatment with rituximab
 - Treating physician has decided to treat the patient with a 90Y-Zevalin regimen
 - The patient is >= 18 years of age
 - Patient has given informed consent
Exclusion Criteria
- Patient is unwilling or unable to give informed consent
 - Patient is participating in another clinical trial

Trial Summary

Enrollment Goal
30
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Zevalin (Ibritumomab tiuxetan, BAY86-5128)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Belgium

Status
Completed
 

Trial Design